Skip to content

Benjamin Hohl, Chief Financial Officer at Enliven Therapeutics, sold ELVN on Sep 17, 2026

Data as of Oct 16

▼ SELL$177K3,535 shares at $50.03Benjamin Hohl Chief Financial OfficerELVN Enliven Therapeutics, Inc.
Watch ELVN
Traded
Sep 17, 2026
Disclosed
Sep 21, 2026
Filed
4 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Benjamin Hohl, Chief Financial Officer at Enliven Therapeutics, sold ELVN on Sep 17, 2026TRADEDDISCLOSED
ELVNSimilar stocks (XLV — its sector index fund), rebased to ELVN's price on the disclosure day
ELVN since disclosure
−23.6%
after the sale
Similar stocks (XLV) since disclosure
+4.6%
XLV — its sector index fund

Change in closing price from Sep 21, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLBenjamin Hohl Chief Financial OfficerELVN Enliven Therapeutics, Inc.$14.9Kdisclosed Sep 21 · filed 4 days after the trade
  2. ▼ SELLBenjamin Hohl Chief Financial OfficerELVN Enliven Therapeutics, Inc.$111Kdisclosed Sep 21 · filed 4 days after the trade

See every trade on ELVN →